Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
$6.27
-5.1%
$5.65
$4.02
$15.10
$340.05M2.11.79 million shs742,766 shs
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$20.52
-3.7%
$19.01
$7.48
$29.82
$366.73M1.29220,717 shs144,821 shs
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
$3.53
$1.12
$11.30
$96.26M2.274.33 million shs1.20 million shs
XOMA Co. stock logo
XOMA
XOMA
$23.85
-3.0%
$23.91
$18.35
$35.00
$285.41M0.9431,640 shs35,900 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
0.00%-5.65%-5.86%+8.48%+1.54%
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
0.00%-4.51%+3.48%-2.43%+115.32%
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
XOMA Co. stock logo
XOMA
XOMA
0.00%-5.54%-11.63%+15.05%-5.66%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
4.1086 of 5 stars
3.52.00.04.60.62.51.3
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
3.2703 of 5 stars
3.22.00.00.04.11.71.9
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
XOMA Co. stock logo
XOMA
XOMA
4.2497 of 5 stars
3.52.00.03.03.63.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
3.00
Buy$14.33128.78% Upside
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
2.40
Hold$36.4077.39% Upside
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
0.00
N/AN/AN/A
XOMA Co. stock logo
XOMA
XOMA
3.00
Buy$69.50191.40% Upside

Current Analyst Ratings Breakdown

Latest SNSS, EBS, RIGL, and XOMA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
XOMA Co. stock logo
XOMA
XOMA
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$104.00
5/7/2025
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$20.00 ➝ $23.00
4/17/2025
XOMA Co. stock logo
XOMA
XOMA
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$35.00
4/1/2025
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
3/28/2025
XOMA Co. stock logo
XOMA
XOMA
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$104.00 ➝ $104.00
3/21/2025
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
3/19/2025
XOMA Co. stock logo
XOMA
XOMA
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$104.00 ➝ $104.00
(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
$930.30M0.37$0.70 per share8.92$12.51 per share0.50
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$203.08M1.81N/AN/A($1.64) per share-12.51
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
$2.07M0.00N/AN/A$1.42 per share0.00
XOMA Co. stock logo
XOMA
XOMA
$13.05M21.88N/AN/A$7.72 per share3.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
-$760.50M-$2.71N/A3.03N/A-18.55%-9.91%-3.31%8/5/2025 (Estimated)
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
-$25.09M$2.07146.5819.54N/A2.46%-14.80%3.03%8/5/2025 (Estimated)
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
-$23.33M-$2.70N/AN/AN/AN/A-179.05%-72.27%N/A
XOMA Co. stock logo
XOMA
XOMA
-$40.83M-$1.15N/AN/AN/A-151.34%-24.95%-9.64%8/12/2025 (Estimated)

Latest SNSS, EBS, RIGL, and XOMA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
XOMA Co. stock logo
XOMA
XOMA
-$0.26$0.06+$0.32$0.06$6.75 million$15.91 million
5/7/2025Q1 2025
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
$0.49$0.71+$0.22$1.19$218.50 million$222.20 million
5/6/2025Q1 2025
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$0.14$0.63+$0.49$0.63$43.87 million$53.33 million
3/17/2025Q4 2024
XOMA Co. stock logo
XOMA
XOMA
-$0.29-$0.46-$0.17-$0.46$8.75 million$8.70 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
N/AN/AN/AN/AN/A
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
N/AN/AN/AN/AN/A
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
N/AN/AN/AN/AN/A
XOMA Co. stock logo
XOMA
XOMA
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
1.30
2.88
1.47
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
N/A
1.96
1.87
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
N/A
7.74
7.74
XOMA Co. stock logo
XOMA
XOMA
1.28
7.52
7.52

Institutional Ownership

CompanyInstitutional Ownership
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
78.40%
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
66.23%
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
28.41%
XOMA Co. stock logo
XOMA
XOMA
95.92%

Insider Ownership

CompanyInsider Ownership
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
1.20%
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
9.48%
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
4.22%
XOMA Co. stock logo
XOMA
XOMA
9.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
2,42054.28 million53.53 millionOptionable
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
16017.87 million16.02 millionOptionable
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
2418.09 millionN/AOptionable
XOMA Co. stock logo
XOMA
XOMA
1011.97 million10.94 millionOptionable

Recent News About These Companies

XOMA (NASDAQ:XOMA) Upgraded by Wall Street Zen to "Buy" Rating
XOMA Royalty Reports Strong Q1 2025 Results
XOMA Royalty: Q1 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Emergent BioSolutions stock logo

Emergent BioSolutions NYSE:EBS

$6.26 -0.34 (-5.08%)
Closing price 06/13/2025 03:59 PM Eastern
Extended Trading
$6.24 -0.02 (-0.32%)
As of 06/13/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Rigel Pharmaceuticals stock logo

Rigel Pharmaceuticals NASDAQ:RIGL

$20.52 -0.78 (-3.66%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$20.70 +0.18 (+0.88%)
As of 06/13/2025 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Sunesis Pharmaceuticals stock logo

Sunesis Pharmaceuticals NASDAQ:SNSS

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

XOMA stock logo

XOMA NASDAQ:XOMA

$23.80 -0.80 (-3.25%)
As of 06/13/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.